Holen Sie sich die Stockscreener-App
0.4411
3.06%
-0.0164
Schlusskurs vom Vortag:
$0.4575
Offen:
$0.459
24-Stunden-Volumen:
2.13M
Relative Volume:
0.57
Marktkapitalisierung:
$24.82M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-28.53M
KGV:
-0.2477
EPS:
-1.7805
Netto-Cashflow:
$-20.10M
1W Leistung:
+38.59%
1M Leistung:
+47.83%
6M Leistung:
-71.57%
1J Leistung:
-82.19%
1-Tages-Spanne:
$0.4035
$0.459
1-Wochen-Bereich:
$0.3201
$0.476
52-Wochen-Spanne:
$0.25
$3.69
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.438 | 25.92M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,107.43 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.97 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
231.63 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.00 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.30 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Medicus Pharma advances Teverelix in prostate cancerICYMI - Proactive financial news
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy - MyChesCo
Medicus Pharma Ltd (MDCXW) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Montgomery Advertiser
This $9 SpaceX Stock Has Crazy Potential Geena Davis (jBXkEb6qgn) - Mshale
This $9 SpaceX Stock Has Crazy Potential Ottawa News (6IhxvTriSq) - Fathom Journal
Medicus Pharma Ltd (MDCXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the United States Food and Drug Administration (FDA) seeking Rare Pediatric Disease Designation for its investigational product Skinject® for the indication of Gorlin syndrome. - Bitget
Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer - Proactive financial news
Medicus advances Teverelix and SkinJect programs with key regulatory filings - Proactive financial news
Small cap wrap: Medicus Pharma, First Phosphate, Standard Uranium... - Proactive financial news
Medicus Dips on FDA Nod - Baystreet.ca
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome - Proactive financial news
Medicus Pharma seeks rare pediatric disease status for patch - Investing.com
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma seeks rare pediatric disease status for patch By Investing.com - Investing.com UK
SkinJect cancer patch seeks FDA rare pediatric status for Gorlin kids - Stock Titan
Medicus Pharma files for RPDD for SkinJect in gorlin syndrome - grafa.com
Medicus Seeks UAE Approval for Genomics-Based Endometriosis Trial - MyChesCo
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma on Bloomberg World - South Bend Tribune
MDCX News | MEDICUS PHARMA LTD (NASDAQ:MDCX) - ChartMill
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - South Bend Tribune
Medicus Pharma (NASDAQ:MDCX) Share Price | RNS News, Quotes, & Charts | MDCX | - Proactive Investors
Small cap wrap: Fineqia, Phunware, Medicus Pharma... - Proactive financial news
Medicus Pharma Submits Ind Application for PRECISION-E2 Phase 2A Study of Teverelix in Endometriosis in United Arab Emirates - marketscreener.com
Medicus Pharma files IND for genomics-enabled endometriosis trial in UAE - Yahoo! Finance Canada
Medicus Pharma submits IND application for endometriosis trial By Investing.com - Investing.com Australia
Medicus Pharma submits IND application for endometriosis trial - Investing.com
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program - The Manila Times
Medicus Pharma Ltd. Submits IND Application for Innovative PRECISION-E2 Phase 2a Clinical Trial in Endometriosis - Quiver Quantitative
Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase - GlobeNewswire
Medicus Pharma submits endometriosis IND in Abu Dhabi - grafa.com
MDCX Q1 2026 Earnings: EPS Miss as Losses Deepen, Stock DeclinesRevenue Growth Outlook - newsline.com
ICYMI: Medicus Advances SkinJect Into Registrational Study for Rare Disorder - MyChesCo
Small cap wrap: Grey Matters Health, Medicus Pharma, ReconAfrica, EnWave... - Proactive financial news
Medicus submits EU filing for Teverelix prostate cancer study - Investing.com UK
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):